Subscribe To
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805 (KRASG12D) expected to begin clinical development in mid-2023 Growing pipeline of development-stage assets, including RMC-0708 (KRASQ61H), that target every major RAS cancer mutation hotspot Webcast today at 4:30 p.m. […] The post Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Resu...
Read More
Posted: Feb 27 2023, 21:05
Author Name: forextv
Views: 101917